1. Home
  2. AKBA vs BYND Comparison

AKBA vs BYND Comparison

Compare AKBA & BYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.89

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

Logo Beyond Meat Inc.

BYND

Beyond Meat Inc.

HOLD

Current Price

$8.29

Market Cap

231.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AKBA
BYND
Founded
2007
2009
Country
United States
United States
Employees
194
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Packaged Foods
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
248.3M
231.6M
IPO Year
2014
2018

Fundamental Metrics

Financial Performance
Metric
AKBA
BYND
Price
$0.89
$8.29
Analyst Decision
Strong Buy
Sell
Analyst Count
3
7
Target Price
★ $4.67
$0.83
AVG Volume (30 Days)
★ 6.3M
1.3M
Earning Date
05-07-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 93.94
24.69
EPS
N/A
★ N/A
Revenue
N/A
★ $275,496,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.36
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$0.81
$0.40
52 Week High
$3.19
$15.47

Technical Indicators

Market Signals
Indicator
AKBA
BYND
Relative Strength Index (RSI) 40.12 39.52
Support Level $0.85 $0.65
Resistance Level $0.98 $12.52
Average True Range (ATR) 0.05 0.79
MACD -0.00 -0.63
Stochastic Oscillator 1.40 3.48

Price Performance

Historical Comparison
AKBA
BYND

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

About BYND Beyond Meat Inc.

Beyond Meat Inc is a provider of plant-based meat company offering a portfolio of revolutionary plant-based meats. It builds meat directly from plants, an innovation that enables consumers to experience the taste, texture and other sensory attributes of popular animal-based meat products while enjoying the nutritional and environmental benefits of eating plant-based meat product It has products such as burgers, sausage, ground beef, jerky, meatballs and chicken. The company generates revenue from sales of its products to the customers across mainstream grocery, mass merchandiser, club store, convenience store and natural retailer channels and various food-away-from-home channels, including restaurants, foodservice outlets and schools, mainly in the United States.

Share on Social Networks: